Article
Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
Journal of gastroenterology and hepatology - 1 Jan 2010
Vassiliadis Themistoklis G, Giouleme Olga, Koumerkeridis Georgios, Koumaras Haralabos, Tziomalos Konstantinos, Patsiaoura Kalliopi, Grammatikos Nikolaos, Mpoumponaris Alexandros, Gkisakis Dimitrios, Theodoropoulos Konstantinos, Panderi Athanasia, Katsinelos Panagiotis, Eugenidis Nikolaos
Abstract excerpt
BACKGROUND AND AIM: Adefovir dipivoxil (ADV) is effective in lamivudine (LAM)-resistant hepatitis B e antigen-negative (HBeAg(-)) chronic hepatitis B (CHB). However, it is unclear whether LAM treatment should be continued in these patients. We aimed to compare the long-term efficacy of adding ADV to ongoing LAM treatment versus switching to ADV monotherapy in LAM-resistant HBeAg(-) CHB. METHODS: Sixty...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.